MYD88 and neoplasm: Additionally, as BTK inhibition has been previously shown to synergize with IRAK inhibition, JH-X-119-01 was co-treated with the BTK inhibitor ibrutinib, which showed synergistic tumor cell-killing effects in MYD88-mutated B-cell lymphoma cells [35].